Compositions and methods for targeted tumor immunotherapy

The compound of any preceding claim, wherein the photocleavable protecting group is an ortho-nitrobenzyl group, a phenacyl ester group, an 8-quinolinyl benzenesulfonate group, a dicoumarin group, a 6-bromo-7-alkoxycoumarin-4-ylmethoxycarbonyl group, a bimane group or a bis-arylhydrazone group.

The compound of any preceding claim, represented by formula (A) or (A′):

• wherein X is C or O, Y is C or N, the photocleavable protecting group is present at one or more of positions 1-9 and Q represents one or more optionally substituted rings or a photocleavable protecting group.

The compound of any preceding claim, wherein the targeting moiety comprises an antibody, an antibody fragment, a ligand, an aptamer or a nanobody.

The compound of any preceding claim, wherein the targeting moiety specifically binds a tumor associated antigen selected from the group consisting of platelet derived growth factor receptor alpha (PDGFRa), activin a receptor type 1 (ACVR1), human epidermal growth factor receptor 2 (Her2), prostate stem cell antigen (PSCA), alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), cancer antigen-125 (CA-125), CA19-9, calretinin, MUC-1, epithelial membrane protein (EMA), epithelial tumor antigen (ETA), tyrosinase, melanoma-associated antigen (MAGE), CD34, CD45, CD99, CD117, chromogranin, cytokeratin, desmin, glial fibrillary acidic protein (GFAP), gross cystic disease fluid protein (GCDFP-15), HMB-45 antigen, protein melan-A (melanoma antigen recognized by T lymphocytes;

• MART-1), myo-D1, muscle-specific actin (MSA), neurofilament, neuron-specific enolase (NSE), placental alkaline phosphatase, synaptophysis, thyroglobulin, thyroid transcription factor-1, the dimeric form of the pyruvate kinase isoenzyme type M2 (tumor M2-PK), an abnormal ras protein, an abnormal p53 protein, mesothelin, EGFRvIII, EGFR1, diganglioside GD2, interleukin 13 receptor α (IL13Rα), fibroblast activation protein (FAP), and L1 cell adhesion molecule (L1CAM).

The compound of any preceding claim, wherein the targeting moiety is selected from the group consisting of trastuzumab, cetuximab, panitumamab, zalutumumab, nimotuzumab, matuzumab, gefitinib, erlotinib, lapatinib, pertuzumab, tositumomab, rituximab, ibritumomab tiuxetan, daclizumab, CEA-scan, colo101, OC125 monoclonal antibody, Ab75705, anti-AFP antibody or fragment thereof, humanized B3, B72.3, bevacizumab, anti-CD99 antibody or fragment thereof, anti-HER2 antibody or fragment thereof and anti-EGFR antibody or fragment thereof.

A pharmaceutical composition comprising a therapeutically effective amount of the compound of any one of the preceding claims, and a pharmaceutically acceptable carrier.